Clomiphene citrate usage pattern in India: A knowledge, attitude, and practice survey among gynecologists
Sonia Malik1, Onkar C Swami2, Sudha Prasad3, Pankaj Talwar4, Sohani Verma5, Kuldeep Jain6, Kanad Dev Nayar7, Gouri Devi8, Umesh Jindal9
1 Program Director, Southend Fertility and IVF, SVASMED Pvt Ltd, 1st Floor, C-1 Market, Vasant Kunj, New Delhi, India 2 Head - Medical Services, Unichem Laboratories Ltd, Jogeshwari (W), Mumbai, India 3 Head and IVF Coordinator, MAMC, Bahadur Shah Jafar Marg, New Delhi, India 4 HOD ART Centre, Army Hospital (Research and Referral) Daulha Kuan, New Delhi, India 5 Senior Consultant - Obstetrics, Gynecology and IVF, Indraprastha Apollo Hospitals, New Delhi, India 6 Director, KJIVF and Laparoscopy Centre, Delhi, India 7 Senior Consultant and HOD, Akanksha IVF Centre, Mata Chanan Devi Hospital, C1 Janak Puri, New Delhi, India 8 Director, Ridge IVF, Gouri Hospitals Ltd, 30 Malkaganj Road, Jawahar Nagar, New Delhi, India 9 Director, Jindal IVF and Sant Memorial Nursing Home, #3050, Sector 20-D, Chandigarh, India
Correspondence Address:
Dr. Sonia Malik Program Director, Southend Fertility and IVF, SVASMED Pvt Ltd, 1st Floor, C-1 Market, Vasant Kunj, New Delhi - 110070 India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2394-4285.162779
|
Introduction: Clomiphene citrate (CC) has an important place in therapy for management of ovulatory dysfunction. The objective of the present survey was to understand the knowledge, attitude, and practice (KAP) of Indian gynecologists toward the use of CC. Materials and Methods: A prospective, cross-sectional, observational, questionnaire-based KAP survey conducted among Indian gynecologists. Out of 22 multiple-choice questions (MCQs), 9 questions were related to efficacy, 5 to safety, and 8 to perception about CC usage in routine clinical practice. Data were summarized by percentages in frequency tables and graphs. Results: Seven hundred seventy-one gynecologists in total across India participated in this survey. The majority of the participants preferred CC in treatment of ovulatory dysfunction associated with polycystic ovary syndrome (PCOS). The ovulation rate was reported to vary 21-60% and the pregnancy rate was noticed to be 11-30% by the majority of the participants. CC was reported to have very good to excellent efficacy and tolerability. Resistance to CC was encountered sometimes. Commonly encountered adverse effects included abdominal/pelvic discomfort or pain, ovarian enlargement, and nausea and vomiting. Frequent complications included multiple gestation, ovarian hyperstimulation syndrome (OHSS), and spontaneous abortion. Quite a few doctors reported congenital malformations with CC therapy. A majority of participants preferred CC in a dose of 50-100 mg/day for 5 days starting on the second or third day of the cycle. Most participants advised natural conception to patients receiving CC therapy. Metformin and gonadotropins were the preferred drugs coadministered with CC treatment. Conclusion: The present KAP survey highlighted CC as a commonly used agent for ovulatory dysfunction, with very good to excellent efficacy and tolerability. |